[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chikungunya-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chikungunya-virus-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,77,99,123,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100607592","against-chikungunya-virus-and-neonatal-infection-100607592",false,"NCT07190560","Against Chikungunya Virus and Neonatal Infection","ConvictionCHIK","Inclusion Criteria:\n\n* Treatment group\n\nNewborn:\n\n* whose mother has a clinical and\u002For laboratory diagnosis of Chikungunya (CHIK) infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Eligible for experimental treatment (called PC-CHIK-V):\n\n  * If the maternal infection was diagnosed between2 days before and the day of delivery, treatment can be administered within the first 12 hours of the newborn's life.\n  * If the maternal infection was diagnosed between 1 day and 2 days after birth, treatment can be administered within 12 hours of diagnosis.\n* Whose holders of parental authority have given free, informed, and written consent prior to any examination required for the research. Parallel Cohort of\n\nUntreated Newborns (parallel observational cohort)\n\nNewborns:\n\n* Whose mother has a clinical and\u002For laboratory diagnosis of CHIK-V infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Not treated with PC-CHIK-V:\n* Monitored in one of the units of the Neonatology Department for at least 5 days from the day of birth.\n* Whose holders of parental authority (or the holder if the mother is the sole holder of parental authority) have been informed of the research and have not objected to the use of data collected during hospitalization for research purposes.\n\nExclusion Criteria:\n\n* Newborns who present at birth with clinical criteria for ahypoxic-ischemic encephalopathy (HIE) that require therapeutic hypothermia according to the national protocol for \"neonatal therapeutic hypothermia\"\n* Newborns who require phototherapy treatment at the time of enrollment using devices with a maximum energy wavelength less than 425 nm and\u002For with an emission bandwidth with a lower limit of \\\u003C375 nm.","ALL","0 Days","2 Days",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection, will have an impact on the proportion of newborns surviving without encephalitis\u002Fencephalopathy (EE) within the first 5 days of life. Researchers will compare results to an observational study of 30 newborns who couldn't have been proposed to participate at the clinical trial, because of delay of diagnosis or delay of transfer to hospital which doesn't allow transfusion or parents not accepting plasma transfusion to the newborn.\n\nParticipants of the clinical trial will:\n\n* receive a transfusion,\n* visit the clinic and undergo biological tests every day until day 7 and once between 1 and 3 months.\n\nParticipant of observational study as part of their regular medical care, and biological data will be reused for the research from the mother's diagnosis until the newborn reaches 3 months of age",[27,28,29,30],"Chikungunya Virus Infection","Neonatal","Transfusion","Encephalopathy","RECRUITING","2026-05-04",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2027-12-01",{"name":41,"class":42},"Centre Hospitalier Universitaire de la Réunion","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100623268","early-phase-1-a-phase-i-study-of-pepgnp-chikv-in-healthy-volunteers-100623268","NCT07394426","A Phase I Study of PepGNP-ChikV in Healthy Volunteers","A Phase I, Dose-escalation, Randomized, Single-blind, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of PepGNP-ChikV, a Synthetic Nanoparticle-based T Cell Next-generational Vaccine Against Chikungunya in Healthy Adults","Inclusion Criteria:\n\n1. Healthy individuals aged ≥18 years to ≤60 years of age, inclusive at time of consent, who are not receiving any excluded concomitant medications as detailed in protocol\n2. Informed consent form signed.\n3. Determined to be eligible by the Investigator based on medical history, physical examination, and screening laboratory testing.\n4. Women of childbearing potential\\* are willing to use effective birth control method(s)\\*\\* for a minimum of 14 days prior to dosing through 90 days after last study vaccination.\n5. Male participants with a partner of childbearing potential must agree to use a highly effective method of contraception (e.g. sterilization or male condom) and refrain from sperm donation during the study and for at least 6 months after the last dose of study drug.\n\n   * An individual who has experienced menarche and who is neither permanently surgically sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) nor post-menopausal. In line with the guidance provided by the Clinical Trial Facilitation Group (CTFG), a post-menopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n\n     * Females of childbearing potential and males must be willing to use a highly effective (acceptable effective contraceptive measures are only acceptable for IMPs with unlikely human teratogenicity \u002F fetotoxicity in early pregnancy) method of contraception (hormonal or abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:\n\n       • combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:\n\n       o oral\n\n       o intravaginal\n\n       o transdermal\n\n       • progestogen-only hormonal contraception associated with inhibition of ovulation\n\n       o oral\n\n       o injectable\n\n       o implantable\n\n       • intrauterine device\n       * intrauterine hormone-releasing system\n       * bilateral tubal occlusion\n       * vasectomised partner\n       * sexual abstinence, (refraining from heterosexual intercourse during the entire period of risk associated with the study treatments (up to Day 407), if this is the preferred and usual lifestyle of the participant).\n\nExclusion Criteria:\n\n1. Self-reported or documented history of laboratory-confirmed chikungunya or other mosquito-borne (arthropod) disease, such as Zika or dengue within 90 days prior to consent.\n2. Travel in the previous 90 days to areas where exposure to flaviviruses such as Zika, dengue, West Nile Fever are common, as well as areas increasing in cases of chikungunya (refer to the following website: Chikungunya virus disease worldwide overview).\n3. Self-reported or documented receipt of any chikungunya (alphavirus) or flavivirus vaccine (investigational or licensed) within 90 days prior to consent.\n4. Receipt of any licensed vaccine, including COVID-19 vaccine, within the 28 days prior to consent or planned receipt within 90 days following last study vaccination (if unplanned circumstances subsequent to enrolment necessitate the receipt of a licensed vaccine e.g. tetanus and rabies, in unavoidable clinical settings, these should be documented in the source documents by the Investigator and not considered a protocol deviation. However, if the licensed vaccine is not urgently required, it should be delayed until at least 90 days following last study vaccination).\n5. Known systemic hypersensitivity to any of the vaccine components (e.g. gold), or history of a life-threatening reaction to vaccines, or to a vaccine containing any of the same substances.\n6. Acute illness according to Investigator judgment especially if febrile (≥38.0°C).\n7. Screening laboratory testing, including vital signs, ECG, urinalysis and blood laboratory tests, must be within the normal reference ranges; if an isolated abnormality is reported, but is assessed by the Investigator as not clinically relevant the participant may be enrolled and the Investigator's judgement documented in the participant's source data. However, the following laboratory values must be within normal ranges: AST, ALT, bilirubin, all measures of renal function, neutrophil count and platelet count. If the Investigator suspects it to be an erroneous result, it can be repeated; the new result should be used for eligibility determination by the Investigator after documenting any clinical significance to any persistently abnormal result.\n8. A positive SARS-CoV-2 polymerase chain reaction (PCR) or a positive rapid SARS-CoV-2 antigen test at Screening.\n9. Women who are pregnant, or lactating,\n10. Calculated body mass index (BMI) \\> 32.0 kg\u002Fm2.\n11. Participation in another clinical study investigating a vaccine, drug, medical device, or medical procedure within 90 days or five half-lives, whichever is longer, prior to consent or planned participation in such a study during the period of this clinical study.\n12. Receipt of immunoglobulins, blood or blood-derived products within 90 days prior to consent or planned receipt during the period of this chikungunya vaccine study.\n13. Known or suspected congenital or acquired immunodeficiency or autoimmune disease; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy, within 90 days prior to consent; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within 90 days prior to consent).\n14. Self-reported or documented Hepatitis surface antigen (HBsAg) positivity or antibody against human immunodeficiency virus (HIV), Hepatitis B core, or Hepatitis C. If the viral screening sample at the screening visit provides a positive result, the participant will be excluded.\n15. Thrombocytopenia (platelet count \\\u003C150,000\u002FmL) or any coagulation disorder considered clinically significant by the Investigator.\n16. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or study completion.\n17. Current alcohol abuse or drug addiction (reported or suspected).\n18. Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study or identified as an immediate family member (i.e. parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study. (i.e. in the employment of the clinical study site).",true,"18 Years","60 Years",{"count":55,"type":21},40,[57],"EARLY_PHASE1","This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60 years of age).\n\nAll participants will undergo a screening visit scheduled for a maximum of 28 days before the enrolment in the clinical study and will provide a blood sample for clinical laboratory tests (complete blood count (CBC)\\*, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, serum creatinine and activated partial thromboplastin time (aPTT), human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)), and a urine sample for tests for Urinary protein, Urinary blood, Urinary glucose and human chorionic gonadotropin β-subunit (βhCG) urine test (only the female participants)) in order to confirm their eligibility for participation in the study.\n\nA total of 40 participants are planned to be enrolled. A randomization system will be used to assign treatment group and participant number at the clinical site.\n\nParticipants will receive 2 injections, 42 days apart. A final visit will take place at Day 407 (i.e. 365 days after last vaccination).\n\nParticipants will be kept under observation for a minimum of one hour after each vaccination to ensure their safety. Reactogenicity data will be collected in all participants after each vaccine injection: solicited injection site reactions will be collected for Days 0-10 and Days 42-52 and solicited systemic reactions will be collected for Days 0-21 and Days 42-63. Unsolicited events will be collected for Days 0-52. Serious adverse events (SAEs) will be reported throughout the study (from inclusion until 12 months after last vaccination). Serious and non-serious medically attended adverse events (MAAEs) and adverse events of special interest (AESIs) will be collected throughout the study (from inclusion until 12 months after last vaccination).",[60,61,27,62,63],"Chikungunya","Chikungunya Fever","Chikungunya Virus Infections","Chikungunya Virus",[65],"Infectious disease, chikungunya, T cell priming vaccine, first in human, healthy volunteer","NOT_YET_RECRUITING","2026-04-23",{"date":69,"type":35},"2026-04-29",{"date":71,"type":21},"2026-08-03",{"date":73,"type":21},"2028-05-01",{"name":75,"class":76},"Gylden Pharma Ltd","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":51,"sex":84,"minAge":52,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100624814","vla1553-403-pregnancy-surveillance-study-100624814","NCT07414524","VLA1553-403 Pregnancy Surveillance Study","Observational Study to Evaluate the Safety of Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Pregnant Women Exposed to the Vaccine in Brazil","Inclusion Criteria:\n\nVLA1553 vaccinated population:\n\n* Women who have received the single dose of the VLA1553 vaccine during pregnancy or within the 30 days prior to the first day of the last menstrual period.\n* Pregnant at the time of enrolment in the study.\n* The participant understands and agrees to comply with the study procedures.\n\nControl group:\n\n* Pregnant at the time of enrolment in the study.\n* Women who have received vaccine(s) approved for use during pregnancy by the MoH and who meet the matching criteria described in the protocol.\n* The participant understands and agrees to comply with the study procedures.\n* Women who have not received the VLA1553 vaccine during pregnancy or within the 30 days prior to the first day of the last menstrual period.\n\nExclusion Criteria:\n\n* Women who do not provide informed consent.\n* Women who are not part of the target population of the pilot vaccination strategy at the time of vaccination.","FEMALE",{"count":86,"type":21},200,"OBSERVATIONAL","This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last menstrual period. A matched comparator cohort of pregnant women vaccinated with routine, pregnancy-recommended vaccines (not exposed to VLA1553) is included. No study procedures beyond routine care are performed.",[27],"2026-02-09",{"date":92,"type":35},"2026-02-17",{"date":94,"type":21},"2026-03-31",{"date":96,"type":21},"2027-12-31",{"name":98,"class":76},"Valneva Austria GmbH",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100587466","phase-4-real-world-effectiveness-safety-and-immunogenicity-of-chikungunya-vaccination-in-populations-at-risk-of-severe-or-complicated-forms-prospective-study-in-la-runion-100587466","NCT06928753","Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion","CHIK-RE-VAC","Inclusion Criteria:\n\n* Eligible for anti-chikungunya vaccination according to french Health Authority (HAS)\n* Beneficiary of social security coverage\n* Signature of informed consent form\n\nExclusion Criteria:\n\n* Pregnant women\n* Vaccine contraindication for patients undergoing medical treatment\n* Persons under guardianship, curatorship or safeguard of justice\n* Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration",{"count":107,"type":21},1800,[109],"PHASE4","Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and\u002For chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.",[27],[113],"Prophylaxis, Safety, Efficacy, Vaccine effectiveness, Chikungunya","2025-07-28",{"date":116,"type":35},"2025-07-29",{"date":118,"type":35},"2025-04-18",{"date":120,"type":21},"2026-10",{"name":41,"class":42},1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":131,"minAge":52,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":43},"100591678","chikungunya-virus-detection-in-semen-100591678","NCT06983548","Chikungunya Virus Detection in Semen","Chikungunya Virus Detection in Semen: Preliminary Study - CHIKSPERM","CHIKSPERM","Inclusion Criteria:\n\n* Patient aged 18 to 45 years.\n* Patient in the acute phase of CHIKV infection, presenting clinical criteria (known onset of clinical symptoms) that, while not specific, can be highly suggestive in an epidemic area, such as: fever, fatigue, nausea, rash, arthritis\u002Farthralgia, myalgia, headaches, conjunctivitis, and ocular pain.\n* Detection of Chikungunya virus genome by Reverse Transcriptase polymerase chain reaction in blood or urine.\n* Patient capable of traveling to the laboratory for sample collection.\n* Patient who has given informed and voluntary consent and signed the consent form.\n* Patient affiliated with a social security system or equivalent.\n\nExclusion Criteria:\n\n* Patients with an ejaculation disorder, unable to provide a semen sample, or with an abnormal semen volume (\\\u003C1.5 mL).\n* Patient with confirmed male infertility.\n* Patients under judicial protection, guardianship, or curatorship.\n* Patient already included in another research protocol.","MALE","45 Years",{"count":134,"type":21},15,[24],"Chikungunya is an arboviral disease transmitted by Aedes mosquitoes, present in intertropical zones and Europe. In August 2024, autochthonous cases appeared on Réunion, followed by a large epidemic. In March 2025, the incidence surpassed 2,000 cases per week. Due to a lack of data, the Haut Comité de Santé Publique issued an unfavorable opinion on using substances of human origin during the epidemic.\n\nAlthough the presence of Chikungunya virus genome in semen has been reported in 7 men, the incidence of viral excretion is unknown. This raises concerns about the risk of sexual transmission and infectivity, especially in assisted reproductive technologies. Previous studies on other arboviruses (Zika, dengue) have explored genital excretion.\n\nThe goal of this prospective pilot study is to investigate Chikungunya virus presence and infectivity in semen, as well as to evaluate the effectiveness of sperm preparation methods in obtaining virus-free gametes. Fifteen patients with acute Chikungunya virus infection will provide blood, urine, and semen samples at different time points (7, 15, 30, 60, 90, and 180 days post-symptom onset). Seminal plasma, native sperm cells, and prepared sperm fractions will be tested for Chikungunya virus RNA at the University Hospital of La Réunion and Toulouse.\n\nThis study will provide insights into viral excretion patterns and help improve the safety of medically assisted reproduction in epidemic situations.",[27],[60,139,140,141],"semen analysis","viral excretion","RT-PCR","2025-05-20",{"date":144,"type":35},"2025-05-21",{"date":146,"type":21},"2025-05",{"date":148,"type":21},"2027-02",{"name":150,"class":42},"University Hospital, Toulouse",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":181,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":122},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.",{"count":160,"type":21},183,[24],"Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[164,165,166,167,168,169,170,171,172,173,174,175,176,27,177,178,179,180],"Leishmaniasis","Leptospirosis","Brucellosis","Q Fever","Rickettsiosis","Tularemia","Psittacosis","Lyme Disease","Tick-borne Encephalitis","Hantaviral Infection Nos","Hepatitis E","Dengue Virus","Zika Virus","West Nile Virus","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[182,165,166,183,184,185,186,187,188,189,190,191,192,193,169,170,194,195],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Lyme disease","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","2025-02-27",{"date":198,"type":35},"2025-03-05",{"date":200,"type":21},"2025-03-03",{"date":202,"type":21},"2025-10-03",{"name":204,"class":42},"University Hospital, Montpellier"]